GlassScriptPhysician profile
Archana Jain
NPI 1720189590
$10,811.15
in general payments reported to CMS, 2019-2025
35 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $414 · 2021: $724 · 2022: $1,031 · 2023: $2,132 · 2024: $2,465 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,924 · Travel and Lodging: $48.00 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,924.05 |
| Travel and Lodging | $48.00 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,740.32 | 2019-2025 | Evenity, Enbrel, Otezla |
| Abbvie INC. | $1,297.31 | 2019-2025 | |
| Pfizer INC. | $1,237.41 | 2019-2025 | |
| Ucb, INC. | $945.87 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $826.05 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $804.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $732.04 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $608.57 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $324.96 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $231.91 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.72 | 2019-2024 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $205.83 | 2019-2024 | Strensiq |
| Sobi, INC | $195.65 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $154.90 | 2019-2024 | Orencia |
| Recordati_rare_diseases_inc. | $124.95 | 2025 | Sylvant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $106.66 | 2023 | Mitraclip |
| Celgene Corporation | $106.41 | 2019 | |
| Genentech USA, INC. | $92.20 | 2019-2024 | Actemra |
| Lilly USA, LLC | $91.45 | 2021-2023 | Taltz |
| Aurinia Pharma U.S., INC. | $88.08 | 2023-2025 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $88.06 | 2023 | Gvoke Hypopen |
| Sandoz INC. | $77.43 | 2023 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $75.69 | 2019 | |
| Fresenius Kabi USA, LLC | $57.68 | 2023-2024 | Idacio |
| Mallinckrodt Enterprises LLC | $55.86 | 2019 | |
| Mallinckrodt Hospital Products INC. | $55.14 | 2022 | |
| Hikma Pharmaceuticals USA | $50.61 | 2019 | |
| Avita Medical Americas, LLC | $48.00 | 2025 | Permeaderm, Recell, Cohealyx |
| Atland Pharmaceuticals, LLC | $37.12 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Genzyme Corporation | $27.01 | 2023 | |
| Kedrion Biopharma, INC. | $23.17 | 2024 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Horizon Therapeutics Plc | $19.78 | 2022 | |
| Boston Scientific Corporation | $19.08 | 2019 | |
| Kyowa Kirin, INC. | $16.97 | 2024 | Crysvita |
| Almatica Pharma LLC | $13.78 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.